David S. Hong MD (@DavidHongMD) ranks #49 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: RASolute 302. CMS Open Payments lists $45,278 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- Lung Cancer: US #49 · 3 physicians engaged
- Presented at AACR 2026 in 2026
- CMS Open Payments lists $45,278 in 2025 general payments.
This Month
What David S. Hong MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies David S. Hong MD
Physicians who reposted David S. Hong MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #49 | — | 3 | 3 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions David S. Hong MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- AACR 2026 · Mini symposiumEmerging novel combinations targeting resistance to KRAS inhibitorsSource: @jyotimalhotramd on X ↗
What Colleagues Are Saying About David S. Hong MD
2026 posts by fellow physicians that mention @DavidHongMD, quoted word for word.
Divarasib as Compared with Sotorasib or Adagrasib in KRASG12C–Mutated NSCLC https://t.co/hgK0FILNr6 Quoting the great @DavidHongMD - First in class is not always the best in class. We will keep seeing this more often. #ESMO26
What’s next for KRASi? Join me & @DavidHongMD #AACR26 Apr 21 for mini symposium on emerging novel combinations targeting resistance to KRAS inhibitors @AACR @KRASKickers https://t.co/8nNwiQ3XEZ
RMC-6236-001 by @KCArbourMD @DavidHongMD and other colleagues on @NEJM for RAS-mutant NSCLC. Take: Daraxonrasib showed a dose-dependent ORR of ~30%. 99% of patients with some toxicity and 4 grade 5 events reported. This is the first oral RAS(ON) agent to show some dose-response signal and likely to expand the options limited to KRAS G12C (Sotorasib and adagrasib). Management of toxicity will be key. #NSCLC #LCSM #KRAS
Trials David S. Hong MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| RASolute 302 | 1 | #40 of 73 | May 31, 2026 |
David S. Hong MD on RASolute 302
Congrats to all RASolute 302 investigators and @RevMedicines! https://t.co/Rx7zp402hc
David S. Hong MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
If KRAS biology ever wins the Noble prize. These Godfathers of RAS should be on the list!#AACR26 @kevansf @frankpmccormick @cjder23 @RevMedicines @KRASKickers https://t.co/QwqYUjWEag
Dr Niamh Coleman sharing the incredible breadth of RAS across all tumors through AACR Genie!#AACR26 https://t.co/YwgroygTjm
The future is here! Watch for it targeting KRASG12V with siRNA! #AACR26 Enfuego Thereapeutics! @ChadPecot @KRASKickers https://t.co/c4CqZjGvza
The Gastric/Esophageal Ca Whisper! #AACR26, @UTMDAnderson https://t.co/nXwqjL0N3T
It is fashion week at #AACR26! The best dressed Onc docs at AACR- @ChristianRolfo and Dr Tina Cascone @UTMDAnderson https://t.co/R8P80KShAX